Apheresis to Obtain Plasma and White Blood Cells in Malies

Key facts

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Principal Investigator

Peter D Crompton, M.D., MD, PhD

National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility

18-55 years · All sexes

Timeline

2011 – 2016

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malaria

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07147400
  Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
  Serum Institute of India Pvt. Ltd.
• RECRUITINGPHASE2NCT07036159
  A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
  GlaxoSmithKline
• ACTIVE NOT RECRUITINGPHASE1NCT06735209
  First-in-Human PfSPZ-LARC2 Vaccination/CHMI
  National Institute of Allergy and Infectious Diseases (NIAID)
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06549257
  Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant
  University of Oxford
• ACTIVE NOT RECRUITINGNANCT06599593
  Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and Malnutrition
  University of California, San Francisco
• RECRUITINGPHASE4NCT06860178
  Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa
  Epicentre
• RECRUITINGPHASE3NCT06923592
  Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
  London School of Hygiene and Tropical Medicine
• RECRUITINGPHASE3NCT07082205
  Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge
  Liverpool School of Tropical Medicine

See all trials for Malaria →